UBS Maintains Buy on AtriCure, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Danielle Antalffy has maintained a Buy rating on AtriCure (NASDAQ:ATRC) and raised the price target from $35 to $40.
October 30, 2024 | 1:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS analyst Danielle Antalffy has maintained a Buy rating on AtriCure and increased the price target from $35 to $40, indicating confidence in the company's future performance.
The increase in the price target from $35 to $40 by UBS suggests a positive outlook on AtriCure's future performance. Maintaining a Buy rating indicates continued confidence from the analyst, which could lead to increased investor interest and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100